Bone Biologics (NASDAQ:BBLG) Posts Earnings Results, Beats Expectations By $0.86 EPS

Bone Biologics (NASDAQ:BBLG) issued its quarterly earnings data on Friday. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.86, FiscalAI reports.

Bone Biologics Stock Performance

Shares of Bone Biologics stock traded down $0.10 on Friday, hitting $1.60. 25,015 shares of the company traded hands, compared to its average volume of 29,963. Bone Biologics has a 12-month low of $1.55 and a 12-month high of $10.08. The firm’s 50-day simple moving average is $2.23 and its 200 day simple moving average is $3.17.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BBLG. Wall Street Zen upgraded Bone Biologics from a “sell” rating to a “hold” rating in a research report on Sunday, September 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bone Biologics in a research note on Tuesday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.